Research  >  About SRI  >  Scientist Profiles
Share:  
|

Scientist profiles G-L

Sunnybrook Research Institute

David Henry, MB ChB, MRCP, FRCP

Senior Scientist

Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room G1 06
Toronto, ON
M4N 3M5

Phone: 416-480-4297
Fax: 416-480-6048

Executive Assistant: Cindy Mastromattei
Phone: 416-480-4297
Fax: 416-480-6048
Email: cindy.mastromattei@ices.on.ca

Education:

  • MB ChB, 1972, Medicine, University of Glasgow, Scotland
  • MRCP, 1974, General Medicine, Joint Colleges of the United Kingdom, UK
  • FRCP (Edin.), 1997, Internal Medicine, Royal College of Physicians, UK

Appointments and Affiliations:

  • Senior scientist, evaluative clinical sciences - Holland Musculoskeletal Research Program, Sunnybrook Research Institute
  • President and chief executive officer, Institute for Clinical Evaluative Sciences
  • Professor, department of medicine, University of Toronto
  • Adjunct professor, clinical pharmacology, faculty of health, University of Newcastle
  • Director, World Health Organization Collaborating Centre for Training in Pharmacoeconomics and Rational Drug Use, University of Newcastle

Research Foci:

  • Pharmacoepidemiology
  • Pharmacoeconomics
  • Medicine and the media
  • Evidence-based medicine
  • Health technology assessment
  • Health services research

Research Summary:

Dr. Henry's research activities focus on patterns of access to medicines and drug pricing issues, and the portrayal of illness and treatment by the media.

Selected Publications:

See current publications list at PubMed.

  1. Henry D, Lim L, Garcia Rodriguez LA, et al.  Variability in risk of major upper gastrointestinal complications with individual NSAIDs:  results of a collaborative meta-analysis.  BMJ 1996;312:1563-1566
  2. Hill S, Mitchell AS, Henry DA.  Problems with pharmacoeconomic analyses. JAMA 2000;283: 2116-2121
  3. Moynihan R, Health I, Henry D. Selling sickness: the pharmaceutical industry and disease-mongering. BMJ 2002;324:886-891
  4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cylcooxygenase: A systematic review of the observational studies of selective and non-selective inhibitors of cyclooxygenase-2.  JAMA 2006;296(13):1633-44
  5. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009;180(2):183-193

Related Links: